

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

GENENTECH, INC. and CITY OF HOPE,)	
)	
Plaintiffs and Counterclaims)	
Defendants,)	C.A. No. 17-1672-GMS
)	
v.)	
)	
PFIZER INC.)	
)	
Defendant and Counterclaim)	
Plaintiff.)	

**STIPULATION AND [PROPOSED] ORDER OF DISMISSAL WITH RESPECT TO
CERTAIN ASSERTED PATENTS**

IT IS HEREBY STIPULATED AND AGREED by the Parties, subject to the approval of the Court, that all claims for infringement of U.S. Patent Nos. 6,417,335, 6,489,447, 6,586,206, 6,620,918, 6,716,602, 7,390,660, 7,449,184, 7,501,122, 8,044,017, 8,460,895, 8,512,983, 8,633,302, 8,691,232, 8,710,196, 8,771,988, 8,822,655, 9,428,766, 9,487,809, 9,493,744, and 9,714,293 (collectively, “the Dismissed Patents”) against Pfizer, Inc. (“Pfizer”) are DISMISSED WITH PREJUDICE and all counterclaims for judgment of non-infringement and invalidity of the Patents are DISMISSED WITHOUT PREJUDICE.

This dismissal is made without prejudice to Genentech Inc. and City of Hope’s (collectively, “Plaintiffs”) ability to assert a Dismissed Patent if (1) Pfizer makes a change to its drug product, PF-05280014 (the subject of Pfizer’s BLA No. 761081), the proposed label for its drug product, or the manufacturing processes disclosed in Pfizer’s BLA No. 761081, and that change materially alters the infringement analysis with respect to any claim of that Dismissed

Patent; or (2) Plaintiffs subsequently discover information not previously provided which establishes that the information provided by Pfizer pursuant to 42 U.S.C. §§ 262(I)(2) or factual representation made by Pfizer in the statement provided according to 262(I)(3)(B) was inaccurate or incomplete when provided, and the newly-discovered information materially alters the infringement analysis with respect to any claim of that Dismissed Patent. In the event that Plaintiffs reassert a Dismissed Patent under either of those circumstances, the parties reserve their rights with respect to the application of the limitation on remedies provided in 35 U.S.C. § 271(e)(6)(B) with respect to that Dismissed Patent. Each Party is to bear its own costs, expenses, and attorneys' fees associated with this action with respect to the Dismissed Patents.

/s/ Jason J. Rawnsley

Frederick L. Cottrell, III (#2555)
Jason J. Rawnsley (#5379)
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 North King Street
P.O. Box 551
Wilmington, DE 19801
(302) 651-7700
cottrell@rlf.com
rawnsley@rlf.com

OF COUNSEL:

William F. Lee
Lisa J. Pirozzolo
Emily R. Whelan
Kevin S. Prussia
Andrew J. Danford
WILMER CUTLER PICKERING
HALE AND DORR LLP
60 State Street
Boston, MA 02109
(627) 526-6000

/s/ Dominick T. Gattuso

Dominick T. Gattuso (#3630)
HEYMAN ENERIO GATTUSO & HIRZEL LLP
300 Delaware Ave. Suite 200
Wilmington, DE 19801
(308) 472-7300
dgattuso@hegh.law

OF COUNSEL:

Thomas J. Meloro
Michael W. Johnson
Diana Santos
Dan Constantinescu
WILLKIE FARR & GALLAGHER LLP
787 Seventh Avenue
New York, NY 10019
(212) 728-8000

Attorneys for Defendant Pfizer Inc.

william.lee@wilmerhale.com
lisa.pirozzolo@wilmerhale.com
emily.whelan@wilmerhale.com
kevin.prussia@wilmerhale.com
andrew.danford@wilmerhale.com

Robert J. Gunther Jr.
WILMER CUTLER PICKERING
HALE AND DORR LLP
7 World Trade Center
250 Greenwich Street
New York, NY 10007
(212) 230-8800
robert.gunther@wilmerhale.com


Robert Galvin
WILMER CUTLER PICKERING
HALE AND DORR LLP
950 Page Mill Road
Palo Alto, CA 94304
(650) 858-6000
robert.galvin@wilmerhale.com

Daralyn J. Durie
Adam R. Brausa
DURIE TANGRI LLP
217 Leidesdorff St.
San Francisco, CA 94111
(415) 362-6666
ddurie@durietangri.com
abrausa@durietangri.com

*Attorneys for Plaintiffs Genentech, Inc.
and City of Hope*

Dated: March 23, 2018

SO ORDERED this 28th day of March, 2018.


United States District Judge